A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors

Conditions

Melanoma, skin

Phase I

What is the purpose of this trial?

This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Recombinant interleukin-12 may kill tumor cells by blocking blood flow to the tumor and by stimulating white blood cells to kill tumor cells. Giving pembrolizumab and recombinant interleukin-12 may work better in treating patients with solid tumors.

  • Trial with
    National Cancer Institute
  • Start Date
    06/23/2018
  • End Date
    08/30/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Stephanie Rosini

  • Last Updated
    11/20/2018
  • Study HIC
    #2000021716